WO2013192565A3 - Use of ferric citrate in the treatment of chronic kidney disease patients - Google Patents
Use of ferric citrate in the treatment of chronic kidney disease patients Download PDFInfo
- Publication number
- WO2013192565A3 WO2013192565A3 PCT/US2013/047134 US2013047134W WO2013192565A3 WO 2013192565 A3 WO2013192565 A3 WO 2013192565A3 US 2013047134 W US2013047134 W US 2013047134W WO 2013192565 A3 WO2013192565 A3 WO 2013192565A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- increase
- iron
- reduce
- kidney disease
- chronic kidney
- Prior art date
Links
- 208000020832 chronic kidney disease Diseases 0.000 title abstract 2
- 229960002413 ferric citrate Drugs 0.000 title abstract 2
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 title abstract 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 8
- 229910052742 iron Inorganic materials 0.000 abstract 4
- 210000002966 serum Anatomy 0.000 abstract 3
- 239000003173 antianemic agent Substances 0.000 abstract 2
- 229940125367 erythropoiesis stimulating agent Drugs 0.000 abstract 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 abstract 1
- 102000008857 Ferritin Human genes 0.000 abstract 1
- 108050000784 Ferritin Proteins 0.000 abstract 1
- 238000008416 Ferritin Methods 0.000 abstract 1
- 102000001554 Hemoglobins Human genes 0.000 abstract 1
- 108010054147 Hemoglobins Proteins 0.000 abstract 1
- 206010022971 Iron Deficiencies Diseases 0.000 abstract 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract 1
- 102000004338 Transferrin Human genes 0.000 abstract 1
- 108090000901 Transferrin Proteins 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052698 phosphorus Inorganic materials 0.000 abstract 1
- 239000011574 phosphorus Substances 0.000 abstract 1
- 239000012581 transferrin Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Abstract
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201590062A EA201590062A1 (en) | 2012-06-21 | 2013-06-21 | APPLICATION OF LEMON-ACID IRON IN THE TREATMENT OF PATIENTS WITH CHRONIC RENOVAL INSUFFICIENCY |
EP20163104.1A EP3730136B1 (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
MX2014015615A MX2014015615A (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients. |
CN201380044271.0A CN104884055A (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
JP2015518623A JP2015535209A (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of patients with chronic kidney disease |
KR1020157001458A KR102150135B1 (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
CA2876982A CA2876982A1 (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
AU2013278000A AU2013278000A1 (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
KR1020207024260A KR20200103855A (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
EP23219273.2A EP4335436A3 (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
ES13807102T ES2796254T3 (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of patients with chronic kidney disease |
EP13807102.2A EP2863906B1 (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
SG11201408521WA SG11201408521WA (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
BR112014032049A BR112014032049A2 (en) | 2012-06-21 | 2013-06-21 | ferric citrate and oral iron supplement |
IL236356A IL236356A0 (en) | 2012-06-21 | 2014-12-18 | Use of ferric citrate in the treatment of chronic kidney disease patients |
HK15110673.6A HK1210013A1 (en) | 2012-06-21 | 2015-10-28 | Use of ferric citrate in the treatment of chronic kidney disease patients |
HK16102352.0A HK1214503A1 (en) | 2012-06-21 | 2016-03-01 | Use of ferric citrate in the treatment of chronic kidney disease patients |
AU2018203205A AU2018203205B2 (en) | 2012-06-21 | 2018-05-08 | Use of ferric citrate in the treatment of chronic kidney disease patients |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261662565P | 2012-06-21 | 2012-06-21 | |
US61/662,565 | 2012-06-21 | ||
US201361757229P | 2013-01-28 | 2013-01-28 | |
US61/757,229 | 2013-01-28 | ||
US201361801050P | 2013-03-15 | 2013-03-15 | |
US201361800618P | 2013-03-15 | 2013-03-15 | |
US61/800,618 | 2013-03-15 | ||
US61/801,050 | 2013-03-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013192565A2 WO2013192565A2 (en) | 2013-12-27 |
WO2013192565A3 true WO2013192565A3 (en) | 2015-10-15 |
Family
ID=49769729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/047134 WO2013192565A2 (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
Country Status (17)
Country | Link |
---|---|
US (3) | US20130345303A1 (en) |
EP (3) | EP3730136B1 (en) |
JP (4) | JP2015535209A (en) |
KR (2) | KR102150135B1 (en) |
CN (2) | CN113244209A (en) |
AU (2) | AU2013278000A1 (en) |
BR (1) | BR112014032049A2 (en) |
CA (1) | CA2876982A1 (en) |
DK (1) | DK3730136T3 (en) |
EA (1) | EA201590062A1 (en) |
ES (1) | ES2796254T3 (en) |
HK (2) | HK1210013A1 (en) |
IL (1) | IL236356A0 (en) |
MX (1) | MX2014015615A (en) |
PL (1) | PL3730136T3 (en) |
SG (2) | SG10201805177PA (en) |
WO (1) | WO2013192565A2 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2563819C2 (en) | 2009-07-21 | 2015-09-20 | Керикс Байофармасьютикалз, Инк. | Drug forms of iron (iii) citrate |
TWI653043B (en) * | 2012-12-20 | 2019-03-11 | 瑞士商伊蘭科動物健康公司 | New use |
WO2014197725A1 (en) | 2013-06-05 | 2014-12-11 | Tricida, Inc. | Proton-binding polymers for oral administration |
EP2856941B1 (en) * | 2013-10-01 | 2020-11-25 | Fresenius Medical Care Deutschland GmbH | Method and apparatuses for determining a patient's daily loss of iron |
SG11201603091QA (en) * | 2013-11-04 | 2016-05-30 | Keryx Biopharmaceuticals Inc | Ferric citrate for reducing cardiac failure in chronic kidney disease patients |
WO2015110968A1 (en) * | 2014-01-23 | 2015-07-30 | Lupin Limited | Pharmaceutical grade ferric citrate and method for its production |
WO2015198304A1 (en) | 2014-06-22 | 2015-12-30 | Dexcel Pharma Technologies Ltd. | Pharmaceutical compositions comprising ferric citrate and methods for the production thereof |
MA41150B1 (en) | 2014-12-10 | 2020-06-30 | Tricida Inc | Proton-binding polymers for oral administration |
CA2978073A1 (en) * | 2015-03-04 | 2016-09-09 | Keryx Biopharmaceuticals, Inc. | Use of ferric citrate in the treatment of iron-deficiency anemia |
CN104688706B (en) * | 2015-04-01 | 2017-07-14 | 成都欣捷高新技术开发有限公司 | A kind of high drug load, ferrum citricum composition of Fast Stripping and preparation method thereof |
WO2016162794A1 (en) * | 2015-04-08 | 2016-10-13 | Leiutis Pharmaceuticals Pvt Ltd | Pharmaceutical compositions of ferric citrate |
WO2016162888A1 (en) * | 2015-04-09 | 2016-10-13 | Actavis Group Ptc Ehf. | Process for preparing pharmaceutical grade ferric citrate |
MA44875A (en) | 2016-05-06 | 2019-03-13 | Tricida Inc | COMPOSITIONS FOR THE TREATMENT OF ACID BASIC DISORDERS |
EP3685831A4 (en) | 2017-09-19 | 2021-06-16 | Japan Tobacco Inc. | Use of ferric citrate in prevention and/or treatment of iron-deficiency anemia in hypermenorrhea patient and/or patient suffering from hypermenorrhea-associated gynecologic disease |
AU2018360867A1 (en) | 2017-11-03 | 2020-04-30 | Tricida, Inc. | Compositions for and method of treating acid-base disorders |
WO2019236639A1 (en) * | 2018-06-04 | 2019-12-12 | Tricida, Inc. | Method of treating acid-base disorders |
WO2020089227A1 (en) | 2018-10-29 | 2020-05-07 | Pharmacosmos Holding A/S | Treating iron deficiency with ferric carboxymaltose |
WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
TW202313072A (en) | 2021-05-27 | 2023-04-01 | 美商凱立克斯生物製藥股份有限公司 | Pediatric formulations of ferric citrate |
CN115024495B (en) * | 2022-06-27 | 2024-03-22 | 北京金康普食品科技有限公司 | Nutritional composition for improving calcium and phosphorus metabolism of nephrosis patient and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998026776A1 (en) * | 1996-12-16 | 1998-06-25 | Chen Hsing Hsu | Method for treating renal failure |
US20090186939A1 (en) * | 2006-01-30 | 2009-07-23 | Keith Chan | Method of Treating Chronic Kidney Disease |
WO2011011541A1 (en) * | 2009-07-21 | 2011-01-27 | Henry Trong Le | Ferric citrate dosage forms |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2261750A1 (en) * | 1996-07-19 | 1998-01-29 | Nikken Chemicals Co., Ltd. | Remedies for hyperphosphatemia |
TWI335218B (en) | 2003-02-19 | 2011-01-01 | Panion & Bf Biotech Inc | Ferric organic compounds, uses thereof and methods of making same |
US8093423B2 (en) | 2003-02-19 | 2012-01-10 | Globoasia, Llc | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
CN1600302A (en) * | 2003-09-22 | 2005-03-30 | 宝龄富锦生技股份有限公司 | Combination of medicine containing ferric citrate, medicine level ferric citrate, preparation method, and diet nutrition containing ferric citrate in medicine level |
US20060134227A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Compositions including iron |
CA3050453C (en) | 2005-08-18 | 2021-07-27 | Panion & Bf Biotech Inc. | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
PT1973549T (en) * | 2006-01-06 | 2016-10-25 | Luitpold Pharm Inc | Methods and compositions for administration of iron |
-
2013
- 2013-06-21 JP JP2015518623A patent/JP2015535209A/en active Pending
- 2013-06-21 PL PL20163104.1T patent/PL3730136T3/en unknown
- 2013-06-21 US US13/924,332 patent/US20130345303A1/en not_active Abandoned
- 2013-06-21 BR BR112014032049A patent/BR112014032049A2/en not_active IP Right Cessation
- 2013-06-21 KR KR1020157001458A patent/KR102150135B1/en active IP Right Grant
- 2013-06-21 ES ES13807102T patent/ES2796254T3/en active Active
- 2013-06-21 WO PCT/US2013/047134 patent/WO2013192565A2/en active Application Filing
- 2013-06-21 EA EA201590062A patent/EA201590062A1/en unknown
- 2013-06-21 EP EP20163104.1A patent/EP3730136B1/en active Active
- 2013-06-21 KR KR1020207024260A patent/KR20200103855A/en not_active IP Right Cessation
- 2013-06-21 EP EP23219273.2A patent/EP4335436A3/en active Pending
- 2013-06-21 AU AU2013278000A patent/AU2013278000A1/en not_active Abandoned
- 2013-06-21 SG SG10201805177PA patent/SG10201805177PA/en unknown
- 2013-06-21 CN CN202110644193.4A patent/CN113244209A/en active Pending
- 2013-06-21 SG SG11201408521WA patent/SG11201408521WA/en unknown
- 2013-06-21 CN CN201380044271.0A patent/CN104884055A/en active Pending
- 2013-06-21 DK DK20163104.1T patent/DK3730136T3/en active
- 2013-06-21 EP EP13807102.2A patent/EP2863906B1/en active Active
- 2013-06-21 CA CA2876982A patent/CA2876982A1/en not_active Abandoned
- 2013-06-21 MX MX2014015615A patent/MX2014015615A/en unknown
-
2014
- 2014-04-25 US US14/262,465 patent/US20140234416A1/en not_active Abandoned
- 2014-10-24 US US14/523,656 patent/US20150079168A1/en not_active Abandoned
- 2014-12-18 IL IL236356A patent/IL236356A0/en unknown
-
2015
- 2015-10-28 HK HK15110673.6A patent/HK1210013A1/en unknown
-
2016
- 2016-03-01 HK HK16102352.0A patent/HK1214503A1/en unknown
-
2018
- 2018-04-10 JP JP2018075243A patent/JP2018138562A/en active Pending
- 2018-05-08 AU AU2018203205A patent/AU2018203205B2/en not_active Ceased
-
2020
- 2020-02-25 JP JP2020029756A patent/JP2020100638A/en active Pending
-
2022
- 2022-02-10 JP JP2022019167A patent/JP2022070945A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998026776A1 (en) * | 1996-12-16 | 1998-06-25 | Chen Hsing Hsu | Method for treating renal failure |
US20090186939A1 (en) * | 2006-01-30 | 2009-07-23 | Keith Chan | Method of Treating Chronic Kidney Disease |
WO2011011541A1 (en) * | 2009-07-21 | 2011-01-27 | Henry Trong Le | Ferric citrate dosage forms |
Non-Patent Citations (6)
Title |
---|
C. BOND ET AL.: "A Meta-Aanalysis Of Ferric Citrate For Hyperphosphatemia: The Effect odf an Oral Iron-Containing Phospahte Binder on Serum Ferritin and Saturated Transferrin in Hemodialysis Patients", NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 27, no. S2, May 2012 (2012-05-01), pages ii490, XP002740672 * |
K. UMANATH ET AL.: "Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESDR on dialysis", HEMODIALYSIS INTERNATIONAL, vol. 17, 15 June 2012 (2012-06-15), pages 67 - 74, XP002740674 * |
M. SIKA ET AL.: "A Dose-Ranging And Efficacy Phase 3 Trial Of Ferric Citrate (FC) As A Phosphate Binder In Dialysis Patients", AM. J. KIDNEY DIS., vol. 57, no. 4, 2011, pages A89, XP002740671 * |
T. CHRISTOPHER ET AL.: "Ferric Citrate: an Iron-Based Oral Phosphate Binder", RIDNEY RES. CLIN. PRACT., vol. 31, 20 June 2012 (2012-06-20), pages A38, XP002740673 * |
WU-CHANG YANG: "An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate", NEPHROL. DIAL. TRANSPLANT., 1 January 2002 (2002-01-01), pages 265 - 270, XP055023585, Retrieved from the Internet <URL:http://ndt.oxfordjournals.org/content/17/2/265.full.pdf#page=1&view=FitH> [retrieved on 20120402] * |
YOKOYAMA KEITARO ET AL: "Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial.", AMERICAN JOURNAL OF NEPHROLOGY 2012, vol. 36, no. 5, 2012, pages 478 - 487, XP008176600, ISSN: 1421-9670 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013192565A3 (en) | Use of ferric citrate in the treatment of chronic kidney disease patients | |
MX2016005734A (en) | Ferric citrate for reducing cardiac failure in chronic kidney disease patients. | |
JO2828B1 (en) | Anti-Hepcidin Antibodies and Uses Thereof | |
WO2009125300A3 (en) | Oxygenation procedures for newborns and devices for use therein | |
MY189333A (en) | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii | |
WO2013106646A3 (en) | Compounds and methods for the inhibition of vcb e3 ubiquitin ligase | |
MY183637A (en) | Compounds and uses thereof for the modulation of hemoglobin | |
WO2013132498A3 (en) | Inhalation of nitric oxide for treating respiratory diseases | |
SG158112A1 (en) | Hepatocyte growth factor (hgf) binding proteins | |
WO2007143098A8 (en) | Hepatocyte growth factor (hgf) binding proteins | |
MX2014011186A (en) | Method of enhancing efficacy of blood transfusions. | |
MY178654A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy | |
MY165499A (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
MX2020000083A (en) | Treatment of coagulation disease by administration of recombinant vwf. | |
WO2010119991A3 (en) | Anti-hgf antibody combinational cancer therapies | |
EA201591424A1 (en) | METHODS OF TREATMENT OF IRON DEFICIENCY WITH SOLUBLE IRON PYROPHOSPHATE | |
WO2010102216A3 (en) | Enhancing coagulation or reducing fibrinolysis | |
Quirolo | How do I transfuse patients with sickle cell disease? | |
MX2014002762A (en) | Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients. | |
WO2012075244A3 (en) | Use of hemoglobin effectors to increase the bioavailability of therapeutic gases | |
WO2014159917A3 (en) | Treatment for exposure to nerve agent | |
WO2014012025A3 (en) | Igf-1 proteins and therapeutic uses thereof | |
NZ725920A (en) | Use of ferric citrate in the treatment of chronic kidney disease patients | |
BR112013031174A2 (en) | chicory for prevention and treatment of neurodegeneration | |
WO2012158776A3 (en) | Combination therapy for treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13807102 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2876982 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/015615 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2015518623 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 122019025430 Country of ref document: BR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013807102 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20157001458 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201590062 Country of ref document: EA Ref document number: A201500437 Country of ref document: UA |
|
ENP | Entry into the national phase |
Ref document number: 2013278000 Country of ref document: AU Date of ref document: 20130621 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014032049 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014032049 Country of ref document: BR Kind code of ref document: A2 Effective date: 20141219 |